Analysts who follow VBI Vaccines Inc (VBIV) on average expect it to increase 165.63% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.
That average rating earns VBI Vaccines Inc an Analyst Ranking of 79, which means it ranks higher than 79 of stocks, based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With VBI Vaccines Inc Stock Today?
VBI Vaccines Inc (VBIV) stock has fallen -6.72% while the S&P 500 is up 1.44% as of 2:18 PM on Tuesday, Dec 1. VBIV is down -$0.23 from the previous closing price of $3.43 on volume of 10,205,423 shares. Over the past year the S&P 500 is higher by 17.98% while VBIV is up 251.65%. VBIV lost -$0.21 per share the over the last 12 months.